Skip to content

Effect of Black Garlic in Abdominal Fatness

Effects of Black Garlic in Abdominal Fatness

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210731005
Enrollment
75
Registered
2021-07-31
Start date
2021-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

abdominal fatness abdominal obesity metabolic syndrome hypertension prediabetes dyslipidemia aged black garlic hypertension prediabetes dyslipidemia metabolic syndrome

Interventions

Subjects will receive 8-9 hard capsules containing placebo,Subjects will receive 8-9 hard capsules containing aged black garlic containing S-allylcysteine (SAC) 1.1mg/day,Subjects will receive 8-9 har
placebo, aged black garlic containing S-allylcysteine (SAC) 1.1mg/day, aged black garlic containing S-allylcysteine (SAC) 2.2mg/day

Sponsors

Agricultural Research Development Agency (ARDA)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-60 years old 2. no prior history of allergy to garlic 3. body mass index 25-35 kg/m2 4. waist circumference >80 and >90 cm in women and men, respectively 5. blood pressure >130/85 mmHg or taking anti-hypertensive medications

Exclusion criteria

Exclusion criteria: 1. allergy to garlic 2. has taken dietary supplements containing garlic within 1 month of enrollment 3. use of anticoagulants within 3 months of enrollment 4. body weight change of 5kg or more within 6 weeks of enrollment 5. blood pressure 180/110 mmHg or higher 6. fasting plasma glucose 300 mg/dL or higher or HbA1c 10% or higher 7. history of type 1 diabetes 8. history of type 2 diabetes which requires medications (those treated with lifestyle intervention only can be enrolled into the study) 9. receiving steroids antibiotics or probiotics within 3 months of enrollment 10. pregnancy and lactation 11. gastrointestinal diseases affecting digestion and absorption, including but not limited to short bowel syndrome, inflammatory bowel diseases, chronic pancreatitis, and prior bariatric surgery 12. uncontrolled cardiovascular diseases, uncontrolled psychiatric disorder, terminal illness 4. bleeding disorder or chronic liver disease 5. current smoking 6. alcohol use of more than 2 standard drinks/day, >5days/week

Design outcomes

Primary

MeasureTime frame
Blood pressure baseline, 2 weeks, and 12 weeks mmHg, body weight and waist circumference baseline, 2 weeks, and 12 weeks kg and cm

Secondary

MeasureTime frame
Laboratory parameters baseline, 2 weeks, and 12 weeks CBC, BUN, Cr, AST, ALT, ALP, PT, aPTT, FPG, HbA1c, cholesterol, TG, HDLc, LDLc, CRP, gut microbiome analysis baseline, 2 weeks, and 12 weeks stool,proteomic analysis baseline, 2 weeks, and 12 weeks urine

Countries

Thailand

Contacts

Public ContactChaniphun Butryee

Mahidol University

chaniphun.but@mahidol.ac.th028002380

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026